Guideline for the management of knee and hip osteoarthritis

Recommendations

Investigational disease-modifying OA drugs (DMOADs)

Pharmacological interventions

Investigational disease-modifying OA drugs (DMOADs)


 

Intervention: Interleukin-1   knee (IL-1) inhibitors –  Knee and/or hip

Recommendation

We do not recommend offering IL-1 inhibitors for people with knee

Strength of recommendation

Strong against recommendation

Quality of evidence

Low

Intervention: Anti-nerve growth factor (NGF) – Knee and/or hip

Recommendation

We suggest not offering NGF for people with knee  and/or hip OA.

Strength of recommendation

Conditional against recommendation

Quality of evidence

Moderate

Intervention: Fibroblast growth factor (FGF) – Knee and/or hip

Recommendation

We do not recommend offering FGF for people with knee and/or hip OA.

Strength of recommendation

Strong against recommendation

Quality of evidence

Very low

Intervention: Colchicine – Knee and/or hip

Recommendation

We suggest not offering colchicine for people with knee and/or hip OA.

Strength of recommendation

Conditional against recommendation

Quality of evidence

Very low

Intervention: Methotrexate – Knee and/or hip

Recommendation

We suggest not offering methotrexate for people with knee  and/or hip OA.

Strength of recommendation

Conditional against recommendation

Quality of evidence

Low

This event attracts CPD points and can be self recorded

Did you know you can now log your CPD with a click of a button?

Create Quick log

Advertising